Duvyzat(Givinostat)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
Formulation:
SUSPENSION
Validity period:
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

DUVYZAT (givinostat) is a histone deacetylase inhibitor approved for treating Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. It modulates gene expression, potentially slowing disease progression by reducing muscle degeneration. The drug is administered orally as a weight-based suspension twice daily with food. Key safety considerations include monitoring for thrombocytopenia, hypertriglyceridemia, and QTc prolongation.  

Clinical trials demonstrated efficacy in delaying functional decline, with a 1.78-second improvement in 4-stair climb time versus placebo over 18 months. Common adverse reactions include diarrhea, abdominal pain, and hematological changes. DUVYZAT requires rigorous adherence to dosing guidelines and regular laboratory monitoring to mitigate risks.

Generic name

Duvyzat(Givinostat)
English name
Givinostat
Alternative Names
Duvyzat
Drug prices
Indications

DUVYZAT is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.

Therapeutic Target
Histone deacetylase (HDAC) inhibitor. The precise mechanism by which DUVYZAT exerts its effect in patients with DMD is unknown.
Active Ingredients
Givinostat hydrochloride monohydrate
Dosage form
SUSPENSION
specifications
Description

DUVYZAT (givinostat) oral suspension contains givinostat hydrochloride monohydrate, a histone deacetylase inhibitor. Givinostat hydrochloride monohydrate is designated chemically as: [6-(diethylaminomethyl)naphthalen-2-yl]methyl[4(hydroxycarbamoyl) phenyl] carbamate hydrochloride monohydrate. The molecular formula is C₂₄H₂₇N₃O₄•HCl•H₂O and the molecular weight is 475.97 g/mol.

Givinostat hydrochloride monohydrate is a white to off-white, non-hygroscopic, crystalline powder that is very slightly to slightly soluble in aqueous media and slightly soluble in ethanol.

DUVYZAT contains givinostat 8.86 mg/mL (equivalent to givinostat hydrochloride monohydrate 10 mg/mL) and the following inactive ingredients: cream flavor, glycerin, non-crystallizing sorbitol solution, peach flavor, polysorbate 20, purified water, saccharin sodium, sodium benzoate, sodium hydroxide, tartaric acid, and tragacanth.

Dosage and Administration

Recommended Evaluation and Testing Before Initiation

Obtain and evaluate baseline platelet counts and triglycerides prior to initiation.

Do not initiate DUVYZAT in patients with a platelet count less than 150 x 10⁹/L.

In patients with underlying cardiac disease or taking concomitant medications that cause QT prolongation, obtain ECGs when initiating treatment, during concomitant use, and as clinically indicated.

Recommended Dosage

The recommended dosage of DUVYZAT is based on body weight and administered orally twice daily with food:

10 kg to less than 20 kg: 22.2 mg (2.5 mL) twice daily

20 kg to less than 40 kg: 31 mg (3.5 mL) twice daily

40 kg to less than 60 kg: 44.3 mg (5 mL) twice daily

60 kg or more: 53.2 mg (6 mL) twice daily

Dosage Modifications for Adverse Reactions

Dosage modifications may be necessary for:

Platelet count <150 x 10⁹/L verified in two assessments one week apart, or

Moderate or severe diarrhea, or

Fasting triglycerides >300 mg/dL verified by two assessments one week apart

First dosage modification:

10 kg to less than 20 kg: 17.7 mg (2 mL) twice daily

20 kg to less than 40 kg: 22.2 mg (2.5 mL) twice daily

40 kg to less than 60 kg: 31 mg (3.5 mL) twice daily

60 kg or more: 39.9 mg (4.5 mL) twice daily

Second dosage modification (if adverse reactions persist):

10 kg to less than 20 kg: 13.3 mg (1.5 mL) twice daily

20 kg to less than 40 kg: 17.7 mg (2 mL) twice daily

40 kg to less than 60 kg: 26.6 mg (3 mL) twice daily

60 kg or more: 35.4 mg (4 mL) twice daily

If adverse reactions persist after the second dosage modification, DUVYZAT should be discontinued.

For QTc interval prolongation: Withhold DUVYZAT if the QTc interval is > 500 ms or the change from baseline is > 60 ms.

Preparation and Administration Instructions

Before use, shake the DUVYZAT suspension for at least 30 seconds by inverting the bottle by 180°.

Visually verify the homogeneity of the suspension.

Using a graduated oral syringe, measure the appropriate volume of suspension corresponding to the prescribed dose.

Administer orally with the provided graduated oral syringe.

Missed Dose

If a dose is missed, patients should not take double or extra doses.

RECOMMENDED ARTICLES
RELATED ARTICLES
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved